Image

Global Viral Vector and Vaccine Market – Industry Trends and Forecast to 2029

  • Medical Devices
  • Upcoming Report
  • Jun 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Viral Vector and Vaccine Market, By Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Workflow Upstream Processing, Downstream Processing, Application (Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Cancer, Genetic Disorders, Infectious Diseases, Others), End Use (Pharmaceutical and Biopharmaceutical Companies, Research Institutes) – Industry Trends and Forecast to 2029

 

Viral Vector and Vaccine Market

Market Analysis and Size

In recent decades, the introduction of innovative therapies such as gene therapy and cell therapy that utilise vectors has produced a lot of excitement in the medical community. Therapies that involve genetic modification, such as the introduction of therapeutic DNA/gene into a patient's body or cell, have shown great potential in the treatment of cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, among other disorders.

Data Bridge Market Research analyses that the viral vector and vaccine market which was USD 746.6 million in 2021, would rocket up to USD 2932.45 million by 2029, and is expected to undergo a CAGR of 18.65% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

A vector is a type of gene delivery device that is used to introduce a transgene into a cell so that it can be reproduced and/expressed. The vector is a DNA molecule that consists of a transgene insert and a longer sequence that serves as the vector's pillar. Isolation, multiplication, or expression of the insert in the target cell are the basic functions of the vector in conveying genetic information to another cell.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Workflow Upstream Processing, Downstream Processing, Application (Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Cancer, Genetic Disorders, Infectious Diseases, Others), End Use (Pharmaceutical and Biopharmaceutical Companies, Research Institutes)

Countries Covered

Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

Market Players Covered

Novasep (France), MerckKGaA (Germany), Charles River Laboratories (U.K), uniQure N.V. (Netherlands),  Waisman Biomanufacturing  (U.S), Creative-Biogene (U.S), Aldevron (U.S), Addgene (U.S), Oxford Biomedica (U.K), Thermo Fisher Scientific Inc (U.S), Fujifilm Corporation (Japan), Spark Therapeutics Inc. (U.S), ABL Inc. (U.S), Boehringer Ingelheim International GmbH. (Germany), Brammer Bio (U.S), Creative Biogene, General Electric (U.S), Pfizer Inc. (U.S)

Market Opportunities

  • Rising Demand for Synthetic Genes
  • Emergence of Next-Generation Vectors

Viral Vector and Vaccine Market Dynamics

Drivers

  • Rising prevalence of cancer and genetic disorders

The rising frequency of cancer, genetic illnesses, and infectious diseases is boosting demand for vector-based gene treatments, cell therapies, and vaccines, which is one of the primary drivers of the global viral vector and vaccine market. Breast cancer, lung cancer, prostate cancer, colon cancer, and rectum cancer are the most frequent cancers. According to the World Health Organization, lung cancer is the leading cause of cancer death, followed by breast cancer and colorectal cancer.

  • Rapid uptake of viral and plasmid vectors for the development of innovative therapies

Novel medicines are rapidly being developed using viral and non-viral vectors. These vectors are useful for delivering a gene to a specific cell or tissue in vivo. Adeno-associated virus, lentivirus, and retrovirus are examples of viral vectors that have been employed in a variety of clinical and preclinical trials evaluating gene and cell therapy products as well as vaccines.

  • Increasing number of clinical studies for the development of gene therapy

The worldwide gene therapy market is now experiencing an increase in clinical trials, providing a profitable potential for the viral vector and plasmid manufacturing business to flourish.

  • Favourable funding scenario for vector-based therapies

High expense of producing and developing a new medicine, preclinical and clinical trials to determine its effectiveness require enough funding. The abundance of grants and finances available for undertaking research and development activities connected to vector-based cell and gene therapies is propelling the viral vector and vaccine market.

Opportunities

The rising prevalence of diseases such as heart disease, cancer, HIV, and haemophilia has necessitated the development of viral vector-based therapeutics, with technological advancements in viral vector manufacturing driving market expansion. Furthermore, expanding biopharmaceutical industry usage of viral vectors and increasing cost-effective treatments are driving market demand. However, in the coming years, the underdeveloped medical industry in some locations, as well as increased government activities in the healthcare R&D sector, will provide profitable chances.

Restraints/Challenges

The main disadvantages of viral vector vaccines are that they represent a more complex production process, they risk genomic integration, development of host-induced neutralizing antibodies to the carrier virus itself can occur, and/or it may not be possible to use the same technology for repeated vaccinations.

This viral vector and vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the viral vector and vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Viral Vector and Vaccine Market

Due to the terrible COVID-19 pandemic, vaccine development against SARS-CoV-2 has been intense, encompassing all conceivable options for providing the worldwide community with safe and effective vaccine candidates in the shortest possible timeframe. Viral vectors, particularly adenovirus-based vectors, have played an important role. Vaccines have also been developed using viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses, and lentiviruses. COVID-19 vaccines have been developed using self-amplifying RNA viral vectors delivered by lipid nanoparticles. Several adenovirus-based vaccine candidates showed robust immune responses in inoculated animals, and mice and primates were protected against challenges. In addition, adenovirus-based vaccination candidates have gone through phase I through phase III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK.

Recent Development

  • In May 2019, Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in infants under the age of two, has been approved by the US Food and Drug Administration.

Global Viral Vector and Vaccine Market Scope

The viral vector and vaccine market is segmented on the basis of type, workflow, application, disease and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Adenovirus
  • Fowlpox Virus
  • Attenuated Yellow Fever
  • Vaccinia Virus Vectors
  • Others

Workflow

  • Upstream Processing
  • Downstream Processing

Application

  • Antisense and RNAi
  • Gene Therapy
  • Cell Therapy
  • Vaccinology

 Disease

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

End-User

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Viral Vector and Vaccine Market Regional Analysis/Insights

The viral vector and vaccine market is analysed and market size insights and trends are provided by country, type, workflow, application, disease and end-user as referenced above.

The countries covered in the viral vector and vaccine market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America is anticipated to dominate the market share due to increasing infectious disease patients.

Asia-Pacific is expected to be fastest growing region in forecast period due to clinical transformation and industrialization of gene therapy manufacturing.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The viral vector and vaccine market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for viral vector and vaccine market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the viral vector and vaccine market. The data is available for historic period 2010-2020.

Competitive Landscape and Viral Vector and Vaccine Market Share Analysis

The viral vector and vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to viral vector and vaccine market.

Some of the major players operating in the viral vector and vaccine market are:

  • Novasep (France)
  • MerckKGaA (Germany)
  • Charles River Laboratories (U.K)
  • uniQure N.V. (Netherlands)
  • Waisman Biomanufacturing  (U.S)
  • Creative-Biogene (U.S)
  • Aldevron (U.S)
  • Addgene (U.S)
  • Oxford Biomedica (U.K)
  • Thermo Fisher Scientific Inc (U.S)
  • Fujifilm Corporation (Japan)
  • Spark Therapeutics Inc. (U.S)
  • ABL Inc. (U.S)
  • Boehringer Ingelheim International GmbH (Germany)
  • Brammer Bio (U.S)
  • Creative Biogene
  • General Electric (U.S)
  • Pfizer Inc. (U.S)

Research Methodology: Global Viral Vector and Vaccine Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The viral vector and vaccine market value is expected USD 2932.45 million by 2029.
The Viral Vector and Vaccine Market is to grow at a CAGR of 18.65% during the forecast by 2029.
On the basis of application, the Viral Vector and Vaccine Market is segmented into Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology.
The major players operating in the Viral Vector and Vaccine Market are Novasep (France), MerckKGaA (Germany), Charles River Laboratories (U.K), uniQure N.V. (Netherlands), Waisman Biomanufacturing (U.S), Creative-Biogene (U.S), Aldevron (U.S), Addgene (U.S), Oxford Biomedica (U.K), Thermo Fisher Scientific Inc (U.S), Fujifilm Corporation (Japan), Spark Therapeutics Inc. (U.S), ABL Inc. (U.S), Boehringer Ingelheim International GmbH. (Germany), Brammer Bio (U.S), Creative Biogene, General Electric (U.S), Pfizer Inc. (U.S).